AEterna Zentaris, Inc. Stock (AEZ.TO)

AEterna Zentaris, Inc. Stock Price

Latest Press Releases regarding AEterna Zentaris, Inc.

Company description

AEterna Zentaris, Inc. logo Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

Visit company website

People involved

Fullname Position
David Dodd Chairman of the Board, President, Chief Executive Officer
Dennis Turpin Chief Financial Officer, Senior Vice President
Richard Sachse Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Jude Dinges Chief Commercial Officer, Senior Vice President
Philip Theodore Senior Vice President, Chief Administrative Officer, Corporate Secretary